Savara

97 articles with Savara

• Savara to Participate in Two Upcoming Investor Healthcare Conferences

  11/15/2021

  Savara Inc. today announced that its management team will present at the following healthcare conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference

• Savara Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/12/2021

  Savara Inc. today reported financial results for the third quarter ending September 30, 2021 and provided a business update.

• Savara to Present at the Jefferies London Healthcare Conference

  11/10/2021

  Savara Inc. today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

• Savara to Present at the Inaugural Piper Sandler Lung Day

  10/7/2021

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a Fireside Chat at the Inaugural Piper Sandler Lung Day on Friday, October 15, 2021 at 10:30 am ET / 7:30 am PT.

• Savara to Participate in Two Upcoming Investor Healthcare Conferences in September 2021

  9/7/2021

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the following healthcare conferences.

• Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sep 03, 2021

  9/3/2021

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the grant of inducement awards to two new employees.

• Savara Announced New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  8/20/2021

  Savara Inc. today announced the grant of inducement awards to two new employees.

• Savara Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/12/2021

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2021 and provided a business update.

• Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

  6/30/2021

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo.

• Savara to Present at the Jefferies Virtual Healthcare Conference

  5/26/2021

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 AM ET / 7:00 AM PT.

• Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit

  5/17/2021

  Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare & Orphan Disease Virtual Summit on Friday, May 21, 2021 at 12:25 PM ET / 9:25 AM PT.

• Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 14, 2021

  5/14/2021

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that on May 11, 2021, the Compensation Committee of the Company’s Board of Directors granted a newly hired employee the option to purchase 175,000 shares of the Company's common stock and restricted stock units covering 100,000 shares of the Company’s common stock.

• Savara Reports First Quarter 2021 Financial Results and Provides Business Update

  5/13/2021

  Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2021 and provided a business update.

• Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option

  3/15/2021

  Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $1.45 per share.

• Savara Announces Pricing of Public Offering of Common Stock - Mar 11, 2021

  3/11/2021

  Savara Inc., an orphan lung disease company, announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share.

• Savara Announces Proposed Public Offering of Common Stock - Mar 10, 2021

  3/10/2021

  Savara Inc., an orphan lung disease company, announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

• 

  Difficult Decisions, Strategic Streamlining Lead to Workforce Reductions

  12/15/2020

  Mergers and acquisitions are a well-known fact in the life sciences industry, and anyone working within the sector knows to expect them at any time.

• Savara Provides Pipeline and Business Update

  12/10/2020

  Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses to Align with Streamlined Development Programs Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex in aPAP

• Savara to Present at the Jefferies Virtual London Healthcare Conference

  11/11/2020

  Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/ . Please co

• Savara Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/5/2020

  Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update.